Αρχική World News Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with... World News Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma Από Ogkologos - 9 Ιουλίου, 2026 179 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Black Patients Are More Likely to Die of Cancer—Here’s How One... 21 Δεκεμβρίου, 2021 Veteran and His Loyal Dog Pass Away Within Hours Of Each... 21 Μαΐου, 2020 Targeting the Accomplice: A Potential Treatment Approach for Rhabdomyosarcoma 3 Αυγούστου, 2022 Husband Moved To Tears After Opening Christmas Gift From Wife 31 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Breaking News: Supreme Court Upholds the Affordable Care Act How does processed and red meat cause cancer and how much... New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients The link between Down syndrome and childhood leukaemia